Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) EBIT Margin (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed EBIT Margin for 6 consecutive years, with 283.4% as the latest value for Q4 2025.

  • Quarterly EBIT Margin changed N/A to 283.4% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 469.3% through Dec 2025, up 48060.0% year-over-year, with the annual reading at 469.3% for FY2025, 48060.0% up from the prior year.
  • EBIT Margin hit 283.4% in Q4 2025 for Bolt Biotherapeutics, up from 355.14% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 283.4% in Q4 2025 to a low of 5329.72% in Q4 2021.
  • Historically, EBIT Margin has averaged 1490.32% across 5 years, with a median of 1058.05% in 2022.
  • Biggest five-year swings in EBIT Margin: skyrocketed 383858bps in 2022 and later plummeted -72184bps in 2024.
  • Year by year, EBIT Margin stood at 5329.72% in 2021, then surged by 72bps to 1491.14% in 2022, then soared by 37bps to 946.19% in 2023, then plummeted by -52bps to 1441.1% in 2024, then soared by 80bps to 283.4% in 2025.
  • Business Quant data shows EBIT Margin for BOLT at 283.4% in Q4 2025, 355.14% in Q3 2025, and 510.53% in Q2 2025.